Lite Strategy
LITS | NASDAQ
$0.86
+$0.01 (+1.57%)
At close: Nov 16, 2026, 4:00 PM ET
$0.86
$0.00 (-0.41%)
After-hours:
Nov 16, 2026, 4:15 PM ET
Lite Strategy Company Profile
Company profile explainedCompany Profile
Lite Strategy, Inc. functions as a clinical-stage pharmaceutical firm, concentrating its efforts on creating innovative and distinct therapeutic solutions for cancer patients. This entity, which was previously known as MEI Pharma, Inc., officially changed its designation to Lite Strategy, Inc. in September 2025. The company was established in 2000 and has its principal operations located in San Diego, California.
Key Executives
| Name | Position |
|---|---|
| Justin J. File | CEO, CFO, Corporate Secretary & Director |
| Anne Frese | Chief People Officer |
| Robert D. Mass | Strategic Advisor |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 26, 2026 | 4 | Filing |
| Oct 26, 2026 | 4 | Filing |
| Oct 26, 2026 | 4 | Filing |
| Oct 26, 2026 | 4 | Filing |
| Oct 26, 2026 | 4 | Filing |
| May 13, 2026 | 8-K | Current Report |
| May 13, 2026 | 10-Q | Quarterly Report |
| Feb 17, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Feb 17, 2026 | 8-K | Current Report |
| Feb 17, 2026 | 10-Q | Quarterly Report |
Lite Strategy
| Country | United States |
| IPO Date | Dec 18, 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Justin J. File |
Contact Details
9920 Pacific Heights Blvd. San Diego,
California 92121 United States
Stock Details
| Ticker Symbol | LITS |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001262104 |
| CUSIP Number | 55279B301 |
| ISIN Number | US55279B3015 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove LITS